{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:08:13Z","timestamp":1779368893082,"version":"3.53.0"},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Chronic respiratory disease increases the risk of severe COVID\u201019. Remdesivir is a globally approved treatment for COVID\u201019. This study examined the relationship between early remdesivir and all\u2010cause in\u2010hospital mortality among patients with chronic respiratory comorbidities during the SARS\u2010CoV\u20102 Omicron era in the United States. Chargemaster and claims data from the HealthVerity database were used in a retrospective comparative effectiveness study (December 2021\u2013April 2025). Adults hospitalized with COVID\u201019 with \u2265\u20091 chronic respiratory comorbidity were included. Patients who received \u2265\u20091 dose of remdesivir in the first 2 days of hospitalization (early remdesivir) were compared with those who did not (comparator). Patient characteristics were balanced using coarsened exact matching and propensity score (PS) matching. Hazard ratios (HRs) and 95% CIs for 28\u2010day all\u2010cause in\u2010hospital mortality were estimated using Cox proportional hazards models for the overall cohort and for the subgroups stratified by supplemental oxygen use. Overall, 40,817 patients were included in the analysis. In the overall matched cohort (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200912,071 per group), early remdesivir was associated with a significant reduction in 28\u2010day all\u2010cause in\u2010hospital mortality risk (PS\u2010matched HR: 0.75 [95% CI: 0.67, 0.83];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01). In the subgroup analysis, early remdesivir was associated with significant reductions in mortality risk in both patients who did not receive supplemental oxygen (PS\u2010matched HR: 0.72 [95% CI: 0.57, 0.90];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01) and those who did receive supplemental oxygen (PS\u2010matched HR: 0.77 [95% CI: 0.69, 0.87];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01). Early remdesivir is associated with improved survival among patients with chronic respiratory disease who are hospitalized with COVID\u201019.\n                  <\/jats:p>","DOI":"10.1002\/jmv.70926","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:43:26Z","timestamp":1776087806000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Remdesivir on All\u2010Cause In\u2010Hospital Mortality in Patients With Chronic Respiratory Comorbidities Who Are Hospitalized With COVID\u201019 in the United States"],"prefix":"10.1002","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1398-3187","authenticated-orcid":false,"given":"Veronika","family":"M\u00fcller","sequence":"first","affiliation":[{"name":"Department of Pulmonology Semmelweis University Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kolditz","sequence":"additional","affiliation":[{"name":"University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Shvachko","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. Foster City CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Oppelt","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. Foster City CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen\u2010Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. Foster City CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos","family":"Lichtman","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. Foster City CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Berry","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. Foster City CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"US Centers for Disease Control and Prevention. COVID Data Tracker https:\/\/covid.cdc.gov\/covid-data-tracker accessed September 10 2025."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2107-13"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7339a2"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14051446"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.09.046"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15089"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07068-0"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00149-5"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.36416\/1806-3756\/e20220041"},{"key":"e_1_2_11_12_1","unstructured":"T.Perry (2024) Letter 149 How Useful is Paxlovid in 2024? Therapeutics Letter. The University of British Columbia."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-087467"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c00489"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature17180"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"e_1_2_11_17_1","unstructured":"US Food and Drug Administration. FDA Approves First Treatment for COVID\u201019 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19 accessed February 14 2023."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.16349"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae333"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad460"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.01.007"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0131"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae202"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-022-02098-9"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae512"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7106a4"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7224a2"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7342a1"},{"key":"e_1_2_11_30_1","unstructured":"US Centers for Disease Control and Prevention. Variants and Genomic Surveillance https:\/\/www.cdc.gov\/covid\/php\/variants\/variants-and-genomic-surveillance.html accessed September 8 2025."},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e40113"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.07.029"},{"key":"e_1_2_11_33_1","unstructured":"National Center for Health Statistics. Percentage of Current Asthma for Adults Aged 18 and Over United States 2019\u20142024. National Health Interview Survey https:\/\/wwwn.cdc.gov\/NHISDataQueryTool\/SHS_adult\/index.html accessed October 28 2025."},{"key":"e_1_2_11_34_1","unstructured":"National Center for Health Statistics. Percentage of COPD Emphysema or Chronic Bronchitis for Adults Aged 18 and Over United States 2019\u20142024. National Health Interview Survey https:\/\/wwwn.cdc.gov\/NHISDataQueryTool\/SHS_adult\/index.html accessed October 28 2025."},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044640"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa691"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10071-23946"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae511"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/v17111438"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad482"},{"key":"e_1_2_11_41_1","unstructured":"Gilead Sciences Inc. FDA Approves Veklury\u00ae (remdesivir) for COVID\u201019 Treatment in Patients With Severe Renal Impairment Including Those on Dialysis https:\/\/www.gilead.com\/news\/news-details\/2023\/fda-approves-veklury-remdesivir-for-covid-19-treatment-in-patients-with-severe-renal-impairment-including-those-on-dialysis accessed March 17 2026."}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.70926","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.70926","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.70926","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:47:41Z","timestamp":1779367661000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.70926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/jmv.70926"],"URL":"https:\/\/doi.org\/10.1002\/jmv.70926","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70926"}}